ONL-1204
- Generic Name
- ONL-1204
- Drug Type
- Biotech
- CAS Number
- 2040964-58-5
- Unique Ingredient Identifier
- XNA75YDV3F
A Study to Evaluate the Safety and Tolerability of ONL1204 in Patients With Macula-off, Rhegmatogenous Retinal Detachment
Phase 1
Completed
- Conditions
- Rhegmatogenous Retinal Detachment - Macula Off
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- ONL Therapeutics
- Target Recruit Count
- 14
- Registration Number
- NCT03780972
- Locations
- 🇦🇺
Save Sight Institute, Sydney Eye Hospital, Sydney, New South Wales, Australia
🇦🇺Royal Adelaide, Melbourne, Victoria, Australia
🇦🇺Queensland Eye Institute, Melbourne, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath